K. Rettig

733 total citations
38 papers, 529 citations indexed

About

K. Rettig is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, K. Rettig has authored 38 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 7 papers in Pediatrics, Perinatology and Child Health and 7 papers in Oncology. Recurrent topics in K. Rettig's work include Attention Deficit Hyperactivity Disorder (7 papers), Epilepsy research and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). K. Rettig is often cited by papers focused on Attention Deficit Hyperactivity Disorder (7 papers), Epilepsy research and treatment (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). K. Rettig collaborates with scholars based in Germany, United States and Switzerland. K. Rettig's co-authors include Rainer Porschen, G Strohmeyer, Barbara Schäuble, Hendrik‐Tobias Arkenau, A. Schreiner, Thomas Löffler, Lukas Radbruch, S. Schwalen, R. Sabatowski and Karl Christoph Klauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

K. Rettig

37 papers receiving 495 citations

Peers

Countries citing papers authored by K. Rettig

Since Specialization

Citations

This map shows the geographic impact of K. Rettig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Rettig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Rettig more than expected).

Fields of papers citing papers by K. Rettig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Rettig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Rettig. The network helps show where K. Rettig may publish in the future.

Co-authorship network of co-authors of K. Rettig

This figure shows the co-authorship network connecting the top 25 collaborators of K. Rettig. A scholar is included among the top collaborators of K. Rettig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Rettig. K. Rettig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A high polymerized grass pollen extract is efficacious and safe in a randomized double‐blind, placebo‐controlled study using a novel up‐dosing cluster‐protocol 2014 ·Allergy ·Ludger Klimek, Johannes Uhlig, Ralph Mösges, K. Rettig, Oliver Pfaar	29
2	Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents? 2011 ·Child and Adolescent Psychiatry and Mental Health ·(unknown), Andreas Kordon, L. Hargarter, Fritz Mattejat, (unknown), K. Rettig, Barbara Schäuble	11
3	Transitioning to OROS^®methylphenidate from atomoxetine is effective in children and adolescents with ADHD 2011 ·Expert Review of Neurotherapeutics ·(unknown), (unknown), (unknown), K. Rettig, Barbara Schäuble	8
4	Exploring the Impact of Once-Daily OROS® Methylphenidate (MPH) on Symptoms and Quality of Life in Children and Adolescents with ADHD Transitioning from Immediate-Release MPH 2011 ·Postgraduate Medicine ·Andreas Kordon, (unknown), (unknown), Fritz Mattejat, K. Rettig, Barbara Schäuble	10
5	Long-Term Assessment of Topiramate for Epilepsy 2011 ·Clinical Drug Investigation ·A. Hufnagel, (unknown), K. Rettig, A. Schreiner, Barbara Schäuble	4
6	Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study 2011 ·Current Medical Research and Opinion ·Christian Wolff, (unknown), (unknown), K. Rettig, Fritz Mattejat, (unknown), (unknown), Barbara Schäuble	9
7	Use of Recombinant Human Parathyroid Hormone(1–84) in Patients with Postmenopausal Osteoporosis 2010 ·Clinical Drug Investigation ·R Möricke, K. Rettig, Thomas D. Bethke	8
8	Effectiveness of Low Dose of Topiramate Following Rapid Titration in Multiply Handicapped Children and Difficult-to-Treat Epilepsy 2009 ·Neuropediatrics ·Gerhard Kluger, Barbara Schäuble, K. Rettig, A. Schreiner, Hans Holthausen	4
9	Exploring efficacy and tolerability outcomes in patients with difficult-to-treat epilepsy receiving adjunctive topiramate at different titration rates - an exploratory study 2009 ·Acta Neurologica Scandinavica ·Christoph Kurth, Barbara Schäuble, A. Schreiner, K. Rettig, B. J. Steinhoff	2
10	Topiramate in patients with epilepsy and intellectual disability 2009 ·Epilepsy & Behavior ·Peter Martin, A. Schreiner, K. Rettig, Barbara Schäuble	10
11	Topiramate in add-on therapy: Results from an open-label, observational study 2007 ·Seizure ·Karsten Krakow, Ulrike Lengler, K. Rettig, A. Schreiner, Barbara Schäuble	11
12	Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis 2005 ·Annals of Allergy Asthma & Immunology ·Bernd Lange, (unknown), K. Rettig, Gabriële Holtappels, Claus Bachert	22
13	Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial 2005 ·Psychopharmacology ·Karl Mann, Klaus Ackermann, Alexander Diehl, D. Ebert, G. Mundle, Helmut Nakovics, Thomas Reker, Goetz M. Richter, Lutz Schmidt, Martin Drießen, K. Rettig, K Opitz, Bernhard Croissant	29
14	Risperidone 2005 ·Journal of Clinical Psychopharmacology ·Frank–Gerald Pajonk, A. Schreiner, Stefan Peters, K. Rettig, Detlef Degner, Eckart Rüther	7
15	Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion 2004 ·International Journal of Colorectal Disease ·Hendrik‐Tobias Arkenau, K. Rettig, Rainer Porschen	17
16	5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer:long-term follow-up results of the adjCCA-01 trial 2003 ·Annals of Oncology ·Hendrik‐Tobias Arkenau, (unknown), K. Rettig, G Strohmeyer, Rainer Porschen	65
17	Driving Ability Under Long-Term Treatment with Transdermal Fentanyl 2003 ·Journal of Pain and Symptom Management ·R. Sabatowski, S. Schwalen, K. Rettig, (unknown), (unknown), Lukas Radbruch	58
18	Initialtherapie mit Risperidon in der Akutbehandlung schizophrener Patienten - eine Interimsanalyse 2003 ·Fortschritte der Neurologie · Psychiatrie ·Frank–Gerald Pajonk, A. Schreiner, (unknown), K. Rettig, Detlef Degner, E. Rüther	5
19	Adjuvant Treatment in Colon Cancer – Protocols of the Study Group Gastrointestinal Oncology 1997 ·Oncology Research and Treatment ·Rainer Porschen, (unknown), (unknown), (unknown), K. Rettig, (unknown), G Strohmeyer	0
20	[An epidemiologic study of the value and limits of physical therapy/exercise therapy in Fontaine stage II arterial occlusive disease]. 1992 ·PubMed ·(unknown), C. Diehm, (unknown), K Breddin, H Gerlach, K. Rettig, (unknown)	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact